In a 12-month , single-centre open-label prospective trial , 180 de novo live-donor kidney transplant recipients at low-immunological risk were randomised to a low-dose cyclosporine group which received a low dose of cyclosporine , short-term intensified EC-MPS dosing ( 2160mg/day to week 6 , 1440mg/day thereafter ) and corticosteroids or a standard-dose cyclosporine group which received a standard dose of cyclosporine , standard EC-MPS dosing ( 1440mg/day ) and corticosteroids .